Locations:
Search IconSearch
November 26, 2025/Cancer/News & Insight

Artificial Intelligence in Oncology (Podcast)

Real-world applications in clinical documentation and trial matching

There are a number of different ways that artificial intelligence (AI) may be coming into play in the field of oncology.

In a recent episode of the Cancer Advances podcast, Jame Abraham, MD, FACP, Chair of the Department of Hematology & Medical Oncology at the Cleveland Clinic Cancer Institute, joins podcast host Dale Shepard, MD, PhD, to share how AI can impact clinicians' work.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Podcast excerpt:

Dale Shepard, MD, PhD: Can you highlight the things we're doing clinical trial basis. So, one of the hard parts about clinical trials is you see a patient in front of you and you say, "Well, I've got all these trials. What might my patient qualify for?" Maybe highlight a little bit about how we're trying to do trial matching activities.

Jame Abraham, MD: As all of us clearly understand, clinical trial is the gold standard of cancer treatment. And here, in the adults in the US, less than 10% of patients go on clinical trial. And that's due to many reasons. One reason is, as you said, it's so complex to understand the criteria, who meets the criteria, who doesn't meet the criteria.

So, the AI-based technology, Cleveland Clinic is partnering with a company to help us to identify patients who can potentially be eligible for certain trials. And they'll help the clinicians to cut through the noise and select the patients for the trial.

Dale Shepard, MD, PhD: And I guess the good part about that is some of these products, if someone might not have qualified because their white blood cell count was too low, it will go back and then tell you, if those numbers change, whether they're now eligible.

Jame Abraham, MD: Right. Which is huge.

Advertisement

Related Articles

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Dr. Gerds
December 8, 2025/Cancer/News & Insight
AI Screening Platform Accelerates Trial Recruitment in Polycythemia Vera

AI-driven tools can streamline enrollment and improve efficiency across clinical trials.

PET scan after CAR T-cell therapy
December 5, 2025/Cancer/Blood Cancers
Case Study: Overcoming Communication Barriers to Enroll Patient in CAR T-Cell Therapy Clinical Trial

Patient achieves complete remission from aggressive marginal zone lymphoma with liso-cel

Dr. Roesch
November 28, 2025/Cancer
Management of Pregnancy-Associated Breast Cancer (Podcast)

Supporting patients during pregnancy and beyond

Dr. Bannow
November 24, 2025/Cancer
Insights About Blood Disorders in Adults

Q&A with new classical hematology program leader

Ad